Abstract
INTRODUCTION
A lung transplant continues to be an effective treatment option for select patients with end stage lung disease. Survival following lung transplant is steadily improving [1] but mortality rates among lung transplant recipients continue to be higher than among those receiving other solid organ transplants including heart, kidney and liver. A continued shortage of organ donors has led to attempts to expand the donor pool and reduce wait list mortality [2] . This approach has led to the use of donors who were once considered unsuitable [3, 4] .
There are no studies to our knowledge investigating the impact of lungs from diabetic donors (DDs) on lung transplant recipients since the implementation of the lung allocation score (LAS). The LAS was implemented by the United Network for Organ Sharing (UNOS) in May 2005 as a new system to allocate organs for lung transplants.
13 159 adult lung transplants were performed between January 2006 and June 2014: Of these, 4278 (32.5%) were SLTs and 8881 (67.5%) were DLTs. We excluded patients who were retransplanted. Initial analysis was performed by comparing this cohort to a control group defined as those receiving a transplant from a non-DD. This cohort was then divided by transplant type and compared directly to their respective control group. The primary end point was risk-adjusted all-cause mortality. Secondary endpoints included acute rejection episodes before discharge, total hospital length of stay and postoperative complications. The presence of diabetes in the donor was based on medical history in the UNOS database.
Statistical analysis
Student's t-test and the chi-square test were used to examine continuous and categorical variables, respectively, for baseline recipient characteristics, donor characteristics and postoperative outcomes. Survival curves were generated by the Kaplan-Meier method and compared using the log-rank test. Cox proportional regression analysis was performed in two steps. First, covariates were run in a univariate analysis as predictors of mortality. Next, covariates with a P-value <0.05 were entered simultaneously in the multivariable Cox model. Covariates missing more than 15% of data in the registry were excluded from the analysis. Statistical significance was defined as P < 0.05. Propensity score matching was used to balance the distribution of confounders and validate the results from our multivariate model. We performed 1:1 matching with a calliper of 0.7. All analyses were performed by using SAS 9.3 (SAS Institute, Cary, NC, USA).
RESULTS

Patient characteristics
SLT recipient characteristics from diabetic and non-DDs before and after matching are shown in Table 1 . The two groups were similar with respect to their indications for transplant and overall cause of death (see Supplementary Tables S1 and S2 ). However, there were differences in the causes of early deaths (defined as those occurring within 1 year). The diabetic cohort was more likely to die of infection, graft failure and respiratory causes and less likely to die of cardiovascular causes. Characteristics of DLT recipients from both cohorts before and after matching are shown in Table 2 . The two groups were similar with respect to their indications for transplant and cause of death (see Supplementary Tables  S1 and S2 ). All characteristics with the exception of race in SLT recipients were comparable after matching.
SLT donor characteristics from the two cohorts are shown in Table 1 . After matching, all donor characteristics with the exception of ethnicity were similar. DLT donor characteristics are shown in Table 2 . All donor variables except ethnicity and clinical infection were insignificant after matching.
Post-transplant outcomes
Recipients of SLT from DDs had longer lengths of stay (25.6 vs 19.9 days, P = 0.013) and were more likely to have postoperative airway dehiscence (2.3% vs 0.86%, P = 0.022). Recipients of DLT from DDs had longer lengths of stay (25.5 vs 30.5 days, P = 0.002) and a higher incidence of postoperative dialysis (6.5% vs 8.8%, P = 0.041). There were no differences between the two groups with respect to acute rejection episode, stroke and airway dehiscence.
Mortality
Initial analysis demonstrated that patients receiving a lung transplant, either single or double, from a DD had worse survival. The log-rank test demonstrated a lower median survival in the group receiving transplants from DD (5.6 vs 5.0 years, P = 0.003) that was corroborated by univariate analysis demonstrating increased mortality (HR 1.19; 95% CI, 1.06-1.34; P = 0.003). We performed additional analyses by dividing this initial cohort into two cohorts by transplant type. These results demonstrate that only SLT from a DD was associated with increased mortality.
Single-lung transplantation
A Kaplan-Meier survival curve comparing SLT from DDs with the control group is shown in Fig. 1A . Median survival was significantly lower in the group receiving transplants from DD (4.68 vs 3.48 years, P = 0.03). The results of the Cox proportional regression analysis are shown in Table 3 . This analysis demonstrates that receiving a lung from a DD is associated with increased mortality (HR 1.28; 95% CI, 1.07-1.54; P = 0.011). We used propensity score matching to validate our multivariate model and ensure that we had adequately controlled for potential confounders such as LAS, donor age, donor body mass index (BMI), donor sex, donor creatinine, ischaemic time as well as other recipient characteristics including age, sex, BMI and creatinine. Of the 310 DDs, 287 were matched to 287 non-DDs. The results verified the multivariate model that receiving a lung from a DD is associated with increased mortality (HR 1.34; 95% CI, 1.03-1.74; P = 0.029). The Kaplan-Meier survival curve from this analysis is shown in Fig. 1A .
Of the 310 DDs, 156 (50.3%) had a history of diabetes for more than 5 years; 124 (40.0%) had a history of diabetes for less than 5 years; and 30 (9.6%) had missing data. As shown in Fig. 2 , we found a statistically significant difference in survival when we compared these two groups. Median survival of the recipient was lower when the donor had had diabetes for a longer time (4.29 vs 2.53 years, P = 0.013). Of the 310 DDs, 157 (50.6%) had insulindependent diabetes; 148 (47.7%) had non-insulin-dependent diabetes; and 5 (1.6%) had missing data. There was no significant difference when comparing these two groups.
Double-lung transplantation
A Kaplan-Meier survival curve comparing DLT from DDs and the control cohort is shown in Fig. 1C . Median survival by log-rank test was not statistically significant between the two groups (5.92 vs 6.45 years, P = 0.089). The results of the Cox proportional regression analysis are shown in Table 4 . This analysis demonstrates that receiving a lung from a DD is not associated with increased mortality (HR 1.11; 95% CI, 0.96-1.29; P = 0.14). Propensity score matching validated our multivariate model (HR 0.94; 95% CI, 0.76-1.16; P = 0.53); the Kaplan-Meier survival curve is shown in Fig. 1B . Subgroup analysis of the 592 DDs indicated that 316 (53.4%) had a history of diabetes for more than 5 years; 221 (37.3%) had a history of diabetes for less than 5 years; and 55 (9.3%) had missing data. There was no statistically significant difference on Kaplan-Meier analysis when comparing these two groups (4.9 vs 6.2 years, P = 0.23).
DISCUSSION
Lung transplant continues to be the gold standard for treatment of patients with end-stage lung disease. The shortage of available organs has prompted significant advances in expanding the donor pool [6] . In this study, we attempted to determine if lungs from DDs can be used with acceptable mortality rates in the recipients.
The International Society for Heart and Lung Transplantation registry demonstrates that recipients of lungs from DDs have increased mortality rates at 1 and 5 years [7] . Reyes et al. also identified donor factors, including diabetes, that were associated with increased mortality on risk-adjusted analysis [8] . These studies, although important in identifying a potential risk factor, included data from the period prior to the implementation of the LAS from both SLT and DLT recipients and did not evaluate the impact of insulin or duration of diabetes. Our study corroborates these prior findings, showing that lungs transplanted from with DDs are associated with increased mortality (HR 1.19; 95% CI, 1.06-1.34; P = 0.003) of the recipients. We further divided the initial cohort into two cohorts by transplant type, because SLT and DLT are different entities with different indications and outcomes. SLT from a DD was associated with increased mortality (HR 1.28; 95% CI, 1.07-1.54; P = 0.011) on multivariate analysis and confirmed by propensity score matching. DLT from a DD was not associated with increased mortality. The exact etiology of the increased mortality associated with SLT is unclear and cannot be ascertained from this retrospective analysis. However, other studies have identified the lungs as another potential target organ of diabetes [9, 10] . This potential diabetic dysfunction, or 'diabetic lung,' has many proposed underlying mechanisms. For the purposes of this paper, we chose to categorize them as intrinsic or extrinsic with respect to the lungs being transplanted. Extrinsic mechanisms include impaired respiratory muscle strength and ventilatory response to hypoxia/hypercapnia. We presume that the possible deleterious effects proposed from these mechanisms are not relevant in this patient population because they are not transferred to the recipient. Intrinsic mechanisms include lung volume, diffusing capacity of the lungs for carbon monoxide (DLCO) and gas exchange [11] . There is agreement that both type 1 and type 2 diabetes mellitus can cause microangiopathy of the pulmonary capillaries, resulting in reduced DLCO. Furthermore, this reduction has been shown to correlate with the severity of the patient's other end organ damage including retinopathy and nephropathy [12] . The evidence suggests that patients with diabetes develop abnormal lung function over time, although the exact clinical impact is not fully known.
On subgroup analysis of SLT recipients, duration of diabetes longer than 5 years was associated with increased mortality compared to those with diabetes for a shorter duration. This finding suggests that a longer duration of diabetes correlates with a more detrimental effect on donor lungs, thereby increasing mortality rates. The current literature is not completely in agreement with regard to the impact of diabetes duration on lung function. However, there appears to be some consensus that an increased duration is associated with a greater decline in pulmonary function tests [13] . Our results suggest that the duration of diabetes is the most important factor in survival in SLT recipients because donors with diabetes for less than 5 years had a median survival comparable to that of non-DDs (4.29 vs 4.68 years) while those with diabetes for more than 5 years had a significantly worse median survival (2.53 years). Data on donor glycaemic control, severity of diabetes and presence of end-organ damage secondary to diabetes were not available. Future studies are needed to directly investigate the effect of these variables on recipient survival.
Interestingly, DLT from DDs was not associated with increased mortality on either multivariate analysis or propensity score matching. This finding suggests that DLT is a more robust and durable procedure than SLT and thus able to withstand the potential deleterious effects of the 'diabetic lung.' Additionally, subgroup analysis of DLT recipients did not show an increased mortality risk in patients who had diabetes for more than 5 years compared to those with diabetes for a shorter length of time.
Previous studies have also demonstrated a survival advantage with DLT [14, 15] .
Recipient variables associated with mortality in SLT and DLT were BMI, age, diabetes mellitus and creatinine. These findings are corroborated by previous studies [16] [17] [18] . Other factors associated with mortality were race match, which has been demonstrated in prior studies [19] . Recipients of lungs from DDs had longer length of stay, which suggests a greater incidence of postoperative complications such as infection and airway dehiscence, but the exact etiology cannot be delineated from the current data set. SLT recipients were more likely to have postoperative airway dehiscence (2.3% vs 0.86%, P = 0.022). Four of the seven patients in the DD cohort with dehiscence had diabetes for more than 10 years, which could predispose them to impaired local wound healing and progressive microangiopathy [20] . However, we can only speculate because of the small sample size and our inability to control for potential confounders including but not limited to immunosuppressive regimens, which is a limitation of this study. This specific complication and increased morbidity have not been documented in previous studies and need to be investigated further.
This study has several limitations related to its retrospective nature and the use of a multi-institutional database. There are inherent limitations including coding errors, missing data and lack of important variables pertinent to this topic such as glycaemic control. The large sample size of this study should make all errors related to coding or missing data random and evenly distributed. We made every effort to validate our data set by excluding covariates missing >15% of registry data and by using both multivariate analysis and propensity score matching to confirm our results. However, UNOS does not include all potential confounders including but not limited to socioeconomic status. Despite these limitations, the UNOS database allows us to study a large population of lung transplant recipients that would not be possible at a single institution.
In conclusion, although DLTs from DDs result in increased length of stay and a higher incidence of postoperative dialysis, they can be performed safely without higher mortality. However, when evaluating DDs for SLTs, caution must be taken because transplanting lungs from these donors is associated with increased mortality. In particular, donors who have had diabetes for a longer time (>5 years) confer a higher mortality risk to SLT recipients compared to those with diabetes for a shorter time. We recommend that potential donors for SLT be evaluated for history and duration of diabetes when determining their suitability for providing a transplant. Additionally, preference should be given to DLT when using lungs from donors with diabetes.
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